Morgan Stanley
MS
$165.81
-0.22%
Morgan Stanley is a global financial services firm operating in the Capital Markets industry. It is a leading institution with a strong presence in investment banking and institutional trading, but its core advantage lies in its massive wealth and asset management franchises.
MS
Morgan Stanley
$165.81
Related headlines
Investment Opinion: Should I buy MS Today?
Based on a synthesis of the available data, the objective assessment for Morgan Stanley is a Hold. The stock's valuation appears reasonable with a forward P/E of 13.3 and a PEG ratio suggesting undervaluation relative to growth. However, this is counterbalanced by significant financial risks, including high leverage and questionable cash flow, alongside recent technical weakness. The shift towards stable wealth management income is a long-term positive, but near-term macroeconomic headwinds and market volatility warrant caution before establishing new positions.
Sign up to view all
MS 12-Month Price Forecast
The analysis yields a neutral stance. Compelling valuation and strong profitability are weighed against significant financial leverage and cyclical risks. The base case of range-bound trading is most probable, with the potential for upside if macro conditions improve.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $215.55 and implied upside of +30.0% versus the current price.
Average Target
$215.55
3 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
3
covering this stock
Price Range
$133 - $216
Analyst target range
No sufficient analyst coverage available. The provided analyst data only includes estimates for EPS and revenue from 3 analysts, but does not contain consensus target prices or a ratings distribution. The recent institutional ratings show actions from firms like JP Morgan (Neutral), Keefe Bruyette & Woods (Outperform), and Barclays (Overweight), indicating a mixed but generally positive view from covering analysts, though a formal consensus summary cannot be constructed from the given data.
Bulls vs Bears: MS Investment Factors
Morgan Stanley presents a mixed picture. Its massive, stable wealth management business and attractive valuation based on forward earnings are strong positives. However, high leverage, negative cash flow, and recent underperformance highlight significant risks, particularly in a volatile macroeconomic environment.
Bullish
- Strong Wealth Management Franchise: $9.3T client assets provide stable, recurring revenue stream.
- Healthy Profitability Metrics: ROE of 15.1% and net margin of 14.7% show efficiency.
- Attractive Valuation Metrics: Forward P/E of 13.3 and PEG of 0.58 suggest undervaluation.
- Solid Revenue Growth: Q4 revenue grew 11.1% YoY, indicating business momentum.
Bearish
- High Financial Leverage: Debt-to-equity ratio of 4.26 is elevated, typical but risky.
- Negative Free Cash Flow: TTM FCF of -$17.9B raises questions on cash generation.
- Recent Price Weakness: Down 7.3% over 3 months, underperforming the market.
- Cyclical Business Exposure: Investment banking and trading revenues are market-sensitive.
MS Technical Analysis
The stock has shown a volatile but overall positive trend over the last six months, rising from around $155 in early October 2025 to a peak near $192 in January 2026 before pulling back. The 6-month price change is positive at 5.97%, significantly outperforming the S&P 500, which declined 2.82% over the same period. However, recent performance has been weak, with the stock down 1.17% over the past month and down 7.30% over the past three months, underperforming the broader market's 3-month decline of 4.63%. The current price of $164.57 sits well above the 52-week low of $94.33 but has retreated significantly from the 52-week high of $192.68, placing it roughly in the middle of its annual range. The stock's 1-month relative strength of 4.08 indicates it has recently outperformed the market despite its negative absolute return, but its 3-month relative strength of -2.67 shows underperformance over that longer short-term horizon. The price action shows a clear peak in mid-January 2026 followed by a sustained downtrend into March, with a recent partial recovery in the final days of March 2026. The stock remains below its early 2026 highs, indicating ongoing pressure, but the recovery from the March low near $154 suggests some near-term support has been found.
Beta
1.21
1.21x market volatility
Max Drawdown
-25.0%
Largest decline past year
52-Week Range
$94-$193
Price range past year
Annual Return
+39.0%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | -0.1% | -3.6% |
| 3m | -8.8% | -4.0% |
| 6m | +5.2% | -2.0% |
| 1y | +39.0% | +16.2% |
| ytd | -8.8% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Revenue for Q4 2025 was $28.86 billion, representing a solid 11.08% year-over-year growth. Profitability metrics are healthy, with a net margin of 14.66% and an operating margin of 19.09% as per the latest valuation data. Quarterly net income has been consistently positive, with Q4 2025 at $4.40 billion, showing stability in earnings generation. Financial health shows a high debt-to-equity ratio of 4.26, which is typical for a large financial institution leveraging its balance sheet. The current ratio is a modest 1.17, indicating adequate short-term liquidity. A significant concern is the negative free cash flow of -$17.89 billion on a TTM basis, which requires analysis of the underlying cash flow statements for context, as large financing activities can distort this figure for banks. Operational efficiency is demonstrated by a strong Return on Equity (ROE) of 15.10%. The company's asset turnover and other efficiency ratios are not explicitly provided in the key metrics, but the consistent profitability and high ROE suggest effective use of shareholder capital. The company's shift towards stable wealth management revenue provides a more predictable earnings stream.
Quarterly Revenue
$28.9B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$-17.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is 16.54, while the forward P/E is lower at 13.31, suggesting analysts expect earnings growth. The PEG ratio is 0.58, which indicates the stock may be undervalued relative to its expected earnings growth rate. Peer comparison data for industry averages is not provided in the valuation inputs. Other valuation multiples include a Price-to-Book ratio of 2.50 and a Price-to-Sales ratio of 2.43. The EV/EBITDA of 24.15 and EV/Sales of 2.63 provide additional context, though the P/E-based metrics are most relevant for this profitable financial firm.
PE
16.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~25x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Morgan Stanley's risk profile is elevated, primarily due to its financial structure and market sensitivity. The high debt-to-equity ratio of 4.26, while common for major banks, exposes the firm to interest rate and refinancing risks. The significant negative trailing-twelve-month free cash flow of -$17.89 billion is a major concern that requires scrutiny of its financing and investing activities, though it may be distorted by large balance sheet operations typical for the industry. Operationally, the company remains exposed to cyclical downturns in capital markets, which can pressure investment banking and institutional trading revenues. Recent news points to broader geopolitical uncertainty creating a 'risk-off' tone in markets, which directly impacts trading volumes and deal flow. Furthermore, the stock's beta of 1.2 indicates it is likely to be more volatile than the broader market, amplifying both upside and downside moves.
FAQ
The primary risks are financial and cyclical. The company has a high debt-to-equity ratio of 4.26, which increases vulnerability to rising interest rates. Its business is sensitive to capital markets activity, which can decline during economic downturns. Additionally, the significant negative free cash flow of -$17.9 billion (TTM) requires careful monitoring, though it may be partly explained by banking operations.
A 12-month base case forecast suggests a trading range between $165 and $185, centered around current levels, assuming earnings meet estimates. A bullish scenario (30% probability) could see a retest of the 52-week high near $193, driven by strong capital markets. A bearish scenario (20% probability) could see a pullback toward $140-$160 if macroeconomic conditions worsen.
Based on the provided data, MS stock appears modestly undervalued. The key signal is its PEG ratio of 0.58, which is well below 1.0, indicating the stock price may not be keeping pace with expected earnings growth. Furthermore, its forward P/E of 13.3 is lower than its trailing P/E of 16.5, suggesting analysts anticipate earnings improvement.
MS presents a nuanced case. It is trading at a reasonable valuation with a forward P/E of 13.3 and appears undervalued based on its PEG ratio of 0.58. However, significant risks like high debt and negative cash flow temper the outlook. It may be suitable for value-oriented, risk-tolerant investors, but is not a clear-cut 'good buy' for all.
MS is more suitable for a long-term investment horizon. Its business model, anchored by the massive wealth management division, is built for steady compounding over time. The stock's beta of 1.2 and exposure to cyclical trading revenues make it volatile and less predictable for short-term trading. Long-term investors can better weather the cycles and benefit from the firm's strategic shift towards stable fees.